Switch theme
Sign up to access all valuation multiples
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
2017
43
LTM Revenue $1.2M
Last FY EBITDA -$3.6M
$293M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cuorips has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cuorips achieved revenue of $0.2M and an EBITDA of -$3.6M.
Cuorips expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cuorips valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $1.2M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$3.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2244% | XXX | XXX | XXX |
| EBIT | -$4.0M | XXX | -$4.0M | XXX | XXX | XXX |
| EBIT Margin | -337% | XXX | -2547% | XXX | XXX | XXX |
| Net Profit | -$4.4M | XXX | -$4.3M | XXX | XXX | XXX |
| Net Margin | -368% | XXX | -2736% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cuorips's stock price is JPY 5930 (or $41).
Cuorips has current market cap of JPY 47.5B (or $326M), and EV of JPY 42.7B (or $293M).
See Cuorips trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $293M | $326M | XXX | XXX | XXX | XXX | $-0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cuorips has market cap of $326M and EV of $293M.
Cuorips's trades at 1588.5x EV/Revenue multiple, and -88.7x EV/EBITDA.
Equity research analysts estimate Cuorips's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cuorips has a P/E ratio of -73.8x.
See valuation multiples for Cuorips and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $326M | XXX | $326M | XXX | XXX | XXX |
| EV (current) | $293M | XXX | $293M | XXX | XXX | XXX |
| EV/Revenue | 244.1x | XXX | 1588.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -88.7x | XXX | XXX | XXX |
| EV/EBIT | -72.4x | XXX | -77.1x | XXX | XXX | XXX |
| EV/Gross Profit | 244.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -73.8x | XXX | -80.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -91.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCuorips's revenue per employee in the last FY averaged $4K, while opex per employee averaged $0.1M for the same period.
Cuorips's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cuorips's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cuorips and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1791% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2589% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cuorips acquired XXX companies to date.
Last acquisition by Cuorips was XXXXXXXX, XXXXX XXXXX XXXXXX . Cuorips acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cuorips founded? | Cuorips was founded in 2017. |
| Where is Cuorips headquartered? | Cuorips is headquartered in Japan. |
| How many employees does Cuorips have? | As of today, Cuorips has 43 employees. |
| Is Cuorips publicy listed? | Yes, Cuorips is a public company listed on TKS. |
| What is the stock symbol of Cuorips? | Cuorips trades under 4894 ticker. |
| When did Cuorips go public? | Cuorips went public in 2023. |
| Who are competitors of Cuorips? | Similar companies to Cuorips include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Cuorips? | Cuorips's current market cap is $326M |
| What is the current revenue of Cuorips? | Cuorips's last 12 months revenue is $1.2M. |
| What is the current EV/Revenue multiple of Cuorips? | Current revenue multiple of Cuorips is 244.1x. |
| Is Cuorips profitable? | Yes, Cuorips is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
